Navigation Links
Watson Confirms Azilect® Patent Challenge
Date:10/5/2010

MORRISTOWN, N.J., Oct. 5 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rasagiline mesylate 0.5 and 1.0 mg tablets.  Watson's rasagiline mesylate tablets are generic versions of Teva Neuroscience, Inc.'s Azilect® Tablets, which are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa.

Teva Neuroscience, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. filed suit against Watson on October 1, 2010 in the United States District Court for the District of New Jersey seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. 5,453,446.  Teva's lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA until November 16, 2013 or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.  

Based on available information, Watson believes it may be a "first applicant" to file an ANDA for the 0.5 and 1.0 mg generic versions of Azilect® and, should its ANDA be approved, may be entitled to 180 days of shared generic market exclusivity with other ANDA applicants that filed on the same day as Watson. For the twelve months ending June 30, 2010, Azilect® had total U.S. sales of approximately $108 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceutica
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson to Present at the Jefferies 2010 Global SpecPharma & European Healthcare Conference
2. HRA Pharma and Watson Pharmaceuticals Expand Marketing Partnership for Novel Emergency Contraceptive to Canada
3. Watson to Present at the Bank of America/Merrill Lynch Global Healthcare Conference
4. Watsons Generic Yasmin® Receives FDA Approval
5. Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics
6. Watson Promotes Robert Stewart to Executive Vice President, Global Operations
7. Watson Confirms Renvela® for Oral Suspension Patent Challenge
8. Watson to Host Conference Call and Webcast to Discuss Second Quarter 2010 Earnings
9. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
10. Watsons Generic Prograf® 5 mg Receives FDA Approval
11. Watson Launches Generic Exelon®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... is being recalled after Health Canada tests confirmed it ... health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health ... recalling the product from retail stores across ... building purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)... Dec. 24, 2014  Actavis plc (NYSE: ... has received a complete response letter from the ... New Drug Application (NDA) for the fixed-dose combination ... of hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... in the receipt of a complete response letter, ...
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12
... of stent timing and type, prasugrel bests clopidogrel, ... shown to block,platelet activity in patients with acute ... cut by more than half the risk of,thrombosis, ... a new,analysis of data from the Trial to ...
... With drug-eluting stents, is the ,crush, or ,culotte, technique ... performed for an,arterial narrowing at the branchpoint of two ... be challenging to achieve full coverage of,both vessels without ... study,will provide interventional cardiologists with new information on which ...
Cached Medicine Technology:TRITON-TIMI 38 Stent Analysis Favors Prasugrel 2TRITON-TIMI 38 Stent Analysis Favors Prasugrel 3Stenting Techniques Vie in Branchpoint Lesions 2
(Date:12/26/2014)... (PRWEB) December 26, 2014 Pentec Health, ... in the state of Pennsylvania for 2014. The awards ... statewide programs of its kind in the country. The ... the Pennsylvania Department of Community and Economic Development, the ... Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses and ... of black one-shoulder cocktail dresses . In addition, all ... at discounted prices, up to 70% off. , ... weeks only. You know, we have thousands of frequent callers ... new items can visit our website for more details. The ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International ... after an 8 year battle with breast cancer. ... in her home in Woodland Hills California after an ... , As the founder and volunteer President ... and championed many of today's greatest breakthroughs in restoring ...
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- Overeating is common during ... eat in moderation, an expert says. "Don,t arrive at ... calories if you know you,ll be attending a party, but ... Ashbey-Pejoves, lead dietitian at Northern Westchester Hospital in Mount Kisco, ... to eat healthy during the day and even to have ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... Webinar: , , What: Coverity Webinar, ... 10 am PT, Where:, http://seminar2.techonline.com/registration/distrib.cgi?s=1346&d=2794 , ... the web at the, ... , Overview: , In this web seminar, ...
... Vista, LLC, a marketing,and information services firm focusing on ... Kevin Grossman, who has been with the company,for seven ... , In his new role, ... HRmarketer Services Group. Mr. Grossman will continue,to report ...
... DiseasePHOENIX, Feb. 12 Although major advances have been ... attention needs to be given to one of the ... -- the painful and often progressive condition called lymphedema, ... so much about cardiovascular disease, few physicians are familiar ...
... Md., Feb. 11 Dialysis Corporation of America (Nasdaq: ... fourth quarter and full year 2008 financial results on Thursday, ... company will also host a conference call in conjunction with ... following morning, Friday, March 6, 2009 at 10:00 AM EST. ...
... Study suggest streamlining of prescribing system to avoid ... -- Doctors often override electronic medication safety alerts ... prescribing drugs for patients, which suggests that physicians ... a U.S. study. , Researchers looked at ...
... Corporation (Nasdaq: RGEN ), a global leader ... today that the Company has received ISO 9001:2000 (ISO) ... and quality systems. ISO certification was granted for ... and related services underlying its Protein A business. ...
Cached Medicine News:Health News:Webinar Alert: Coverity Announces Verification and Validation of Medical Device Software with Static Analysis - A Review of FDA Guidance and Best Practices 2Health News:Kevin Grossman Named President of HRmarketer.com 2Health News:Vascular Experts Call for Increased Awareness of Growing Problem of Lymphedema 2Health News:Vascular Experts Call for Increased Awareness of Growing Problem of Lymphedema 3Health News:Dialysis Corporation of America Announces Fiscal Year 2008 Earnings Release Date 2Health News:Docs Override Most Electronic Drug Warnings 2Health News:Repligen Announces ISO 9001:2000 Certification 2Health News:Repligen Announces ISO 9001:2000 Certification 3
Neuropack Sigma MEB-5500 series evoked potential measuring system is a compact, portable, all-in-one unit....
The Nicolet Bravo is a Multi-application system that can configure to meet the needs of neurophysiology deparent....
... Portable systems of the MYOHANDY ... units of the MYOQUICK - SystemPLUS ... they use acquisition systems of the ... channels (ISA 1002, ISA 1002 EP) ...
... Multi-channels Evoked Potential testing systems are the point ... and shows the extremely high technology level of ... channels headbox BQ 132S combined with Acquisition / ... headboxes: ISA 1002 EP with 2 channels, ISA ...
Medicine Products: